Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate

American journal of obstetrics and gynecology, 151(5), 574-577

DOI 10.1016/0002-9378(85)90141-3 PMID 3976757 Source

Abstract

Eighty pregnant women at high risk of giving birth prematurely were divided randomly into two groups. Treatment with either 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week, or a placebo was given in a double-blind fashion. Imminent premature labor occurred in 29.0% of the treated group and in 59.4% of the control group (p less than 0.025). The rate of premature deliveries was also significantly lower in the treated group (16.1%) than in the control group (37.82%) (p less than 0.05). There were no cases of perinatal death or fetal malformations in either group. The mean birth weight of all infants of the treated group was significantly higher than in those of the control group (3111.9 +/- 905 gm versus 2680 +/- 813.4 gm, p less than 0.05). The results support treatment with progesterone caproate for the prevention of premature labor.

Topics

17-hydroxyprogesterone caproate preterm labor, progesterone prevent premature birth, 17-ohp preterm delivery prevention, progesterone supplementation pregnancy, preventing preterm labor high risk pregnancy, hydroxyprogesterone caproate efficacy, progesterone injections preterm birth, makena premature labor prevention, luteal phase support pregnancy, progesterone therapy threatened preterm delivery

Cite this article

Yemini, M., Borenstein, R., Dreazen, E., Apelman, Z., Mogilner, B. M., Kessler, I., & Lancet, M. (1985). Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. *American journal of obstetrics and gynecology*, *151*(5), 574-577. https://doi.org/10.1016/0002-9378(85)90141-3

Related articles